Alnylam Falls 29% After Reporting Q2 Results
Alnylam Pharmaceuticals (ALNY) shares fell about 29% after the company reported Q2 results and lowered its full-year TTR revenue guidance. The report cited strong Q2 revenue growth and a return to profitability, including Q2 net income of $164.5 million versus a $72.2 million net loss a year earlier. The guidance change drove the reaction.
How this was made
The 30-second read
Why it matters
The guidance cut is likely to drive revisions to full-year estimates and valuation multiples, making the stock’s near-term path dependent on how investors interpret the reason for the reset.
Market read
A same-day guidance reset for the TTR franchise is the key tradable catalyst, overriding positive Q2 revenue and profitability signals.
What to watch
The excerpt does not include the magnitude of the guidance change or segment drivers, so traders may be overreacting without full detail on what caused the TTR revenue outlook reduction.
Background
The piece frames Alnylam’s Q2 as strong on revenue and profitability, but highlights a full-year TTR revenue guidance reduction.
Ticker impact
Alnylam shares plunged after it lowered full-year TTR revenue guidance, despite strong Q2 revenue growth and a return to profitability.
Bearish bias for the next few sessions as investors reprice full-year TTR revenue expectations.
The article’s newest concrete fact is the full-year TTR revenue guidance reduction, which typically overwhelms positive earnings optics when magnitude is large (29% drop).
Market effects
Signals heightened sensitivity in rare-disease/biopharma revenue guidance, especially for TTR franchise expectations.
Limited regional spillover implied; focus is single-name repricing.
Moderate, as TTR-focused investors may reassess peers’ revenue durability, but no peer-specific news is provided.
Counterpoint
The guidance cut could reflect timing or conservatism rather than fundamental demand deterioration, and the Q2 profitability return may support a rebound if investors view the reset as temporary.
Key entities
- companyAlnylam Pharmaceuticals
Subject of the article; reported Q2 results and lowered full-year TTR revenue guidance, triggering a sharp selloff.
